1. Home
  2. TORO vs CRBP Comparison

TORO vs CRBP Comparison

Compare TORO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$6.42

Market Cap

174.5M

ML Signal

HOLD

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$8.86

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
CRBP
Founded
2022
2009
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.5M
190.3M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
TORO
CRBP
Price
$6.42
$8.86
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
19.9K
577.7K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$116.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$2.81
$7.12
52 Week High
$8.50
$20.56

Technical Indicators

Market Signals
Indicator
TORO
CRBP
Relative Strength Index (RSI) 70.22 36.08
Support Level $4.87 $7.62
Resistance Level $6.49 $9.66
Average True Range (ATR) 0.28 0.70
MACD 0.01 -0.16
Stochastic Oscillator 88.81 5.66

Price Performance

Historical Comparison
TORO
CRBP

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: